Acta Dermato-Venereologica (Jan 2022)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

  • Tarja Mälkönen,
  • Pauliina Nuutinen,
  • Taru Hallinen,
  • Erkki Soini,
  • Riikka Nissinen,
  • Christina Wennerstöm,
  • Tapio Rantanen,
  • Johanna H. Hagman,
  • Rauno Harvima,
  • Johanna Höök-Nikanne,
  • Tiina Ilves,
  • Päivi Lintu,
  • Ken Malanin,
  • Iina Soramäki,
  • Kaisa Tasanen,
  • Arja Teho,
  • Katja Vähävihu,
  • Sari Itälinna,
  • Pekka Leinonen,
  • Piia Sarajärvi,
  • Laura Huilaja,
  • Rafael Pasternack

DOI
https://doi.org/10.2340/actadv.v101.910
Journal volume & issue
Vol. 102

Abstract

Read online

Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.

Keywords